MĒ Device for At-Home Skin Rejuvenation

NCT ID: NCT02902718

Last Updated: 2017-03-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-28
• Study Completion Date: 2017-12-31

Brief Summary

The purpose of this pilot study is to evaluate the feasibility of the Mē device for at home facial skin rejuvenation.

Detailed Description

The mē home use device is an FDA approved device for hair removal on all skin types and body regions including the face. The device uses Elōs technology which is a combination of electrical field at radio frequencies (RF) and intense optical energy that are simultaneously applied to the tissue and were found to have synergistic effects. Elōs technology has been used at the clinic for non-ablative skin rejuvenation. The levels of Elōs energy used with the professional devices at the clinic is much higher than the level of energy used by the mē device for home use. The current study was designed to evaluate the safety and efficacy of the mē device for home-use non-ablative skin rejuvenation. Healthy female volunteers, seeking facial skin rejuvenation treatment will be enrolled.

The study includes up to 7 visits at the clinic. The defined areas for treatment are one or more facial sub areas (e.g., forehead, peri-orbital, cheeks, peri oral). Subjects will be provided with the device and will be instructed as to the method of usage. The subjects will perform treatments at the clinic and at home according to the schedule detailed in the intervention section. Follow ups will take place at the 1 and 2 months visits. Optional additional follow up visits will take place 3 and 6 months after the initial treatment. Evaluations will include skin safety, tolerability of the procedure, improvement assessment by the study doctor and subject, satisfaction. Optionally, before/after pictures of follow-up visits vs baseline will be sent to blinded evaluators.

Conditions

Skin Aging; Skin Rejuvenation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

mē device

The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.

Group Type: EXPERIMENTAL

mē

Intervention Type: DEVICE

The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.

Interventions

mē

The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Healthy female between the ages of 25 and 60.

2. Willing to sign Informed consent form and photo release form.

3. Having visible lines and wrinkles in the peri-orbital and peri-oral region of the face (Fitzpatrick elastosis degree 3-6).

4. Able and willing to comply with all visit, treatment and evaluation schedules and requirements.

5. Agree to make no changes in their existing skincare regime, other than use of the study products, during the study period.

6. If female, must be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence).

Exclusion Criteria

1. Subjects who currently use or have used in the prior 30 days any skin products that contain alpha hydroxy acids (AHA) e.g. glycolic, lactic, citric, or mandelic acid containing products or retinol/tretinoin containing products or exfoliating washes, masks or scrubs or other micro-dermabrasion skin care products on the treatment areas.

2. Subjects who are unwilling to maintain their daily skin care regimen for the duration of the study.

3. Subjects who have any skin pathology or condition that could interfere with the evaluation i.e. personal or family history of skin cancer, rosacea and/or requires the use of interfering topical or systemic therapies.

4. Subjects with synthetic or metal implants or permanent cosmetic tattoos in the test areas.

5. Subjects who have a history of abnormal scarring, e.g. keloids or have significant scarring in the areas to be treated.

6. Subjects with bleeding disorders or taking anticoagulation medications, including heavy use of aspirin.

7. Subjects who have participated in any clinical investigation involving the face within the 30 days prior to the first planned treatment or subjects who plan to participate in concomitant facial studies during this trial.

8. Subjects, who are pregnant, were pregnant or gave birth in the last 3 months, are currently breast feeding, or might become pregnant during the course of the study.

9. Subjects who have a history of light triggered seizures.

10. Subjects with prior use of neurotoxins e.g. Botox®, collagen, fat injections and/ or other methods of skin augmentation (enhancement with injected or implanted material) of the face or having had chemical peels within 6 months of initial laser application or planning to so during the course of the study.

11. Subject's use of oral isotretinoin (Accutane®) within 12 months of initial device application or during the course of the study.

12. Subjects having had facial skin treatments with any professional laser, light based, radiofrequency or other devices within the last year.

13. Subjects ever having facial skin treatments with home use laser, light based or radiofrequency or other devices, i.e. PaloVia® or Tria®.

14. Subjects with facial plastic surgery within the last 12 months of the initial laser application or planning to do so during the course of the study.

15. Subjects who have had sun exposure or used a tanning bed 4 weeks prior to the start of the study.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Iluminage Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David J Friedman, MD

Role: PRINCIPAL_INVESTIGATOR

Friedman Laser & Skin Center

Lilach Gavish, PhD

Role: STUDY_DIRECTOR

HUJI

Locations

Friedman Skin & Laser Center

Jerusalem, Israel, Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Noa Makhervax

Role: CONTACT

noa.clinict@gmail.com

+972-52-8874799

Facility Contacts

Noa Makhervax

Role: primary

noa.clinict@gmail.com

+972-52-8874799

Other Identifiers

300-16

Identifier Type: -

Identifier Source: org_study_id